Glytec provides an AI-based technology platform for diabetes and related conditions, centered on its flagship Glucommander cloud-based SaaS for inpatient glycemic management. Glucommander is trusted by 400+ hospitals nationwide to improve patient safety, reduce costs, and shorten lengths of stay. The company plans to expand its platform and advance the development of new technologies addressing diabetes and related comorbidities. It intends to support hospitals in complying with upcoming CMS quality measures for inpatient glycemic control. Glytec emphasizes precision insulin management and data-driven insights to help clinicians individualize care and optimize metabolic health outcomes. The company has closed a $36 million growth investment to scale R&D, expand the platform, and support rapid response to regulatory requirements. Glytec’s core product is the FDA-cleared Glucommander eGlycemic Management System, a software platform that delivers personalized, endocrinologist-level insulin dosing across the hospital-to-home continuum. The eGMS is integrated with EHRs to track blood glucose data, detect glycemic disarray, provide personalized dosing regimens, and accelerate patients into target glucose ranges. Clinical validation includes more than 90 research studies and reported reductions such as a 99.8% decrease in low blood sugar, 36–68% lower 30-day readmissions, and length-of-stay reductions up to 3.2 days. Customers report enterprise-wide utilization at or above 95% of eligible patients, annualized cost savings up to $20,000 per licensed bed, and deployment at more than 300 U.S. hospitals including AdventHealth, Novant Health and Sentara Healthcare. Glytec plans to invest in R&D around patient safety, provider workflows, and analytics, expand integrations with EHRs, mobile apps and other diabetes technologies, and grow headcount to scale its flagship product. The company is headquartered outside of Boston (Waltham, Mass.).

Total raised

$57M

Funding rounds

3

Latest round

Equity

Latest activity

Jun 2025